ZTS · Zoetis Inc.
$75.37
+0.80 (+1.07%)
At close · Jul 24
Market Cap
$31.59B
Shares
419.23M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$9.47B
+2.3%
FY2025
Net Income
$2.67B
+7.5%
FY2025
Gross Margin
71.84%
+1.2pp
FY2025
Diluted EPS
$6.02
+10.1%
FY2025
Operating Cash Flow
$2.9B
-1.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $9.68B – $9.96B | $9.53B | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B | $6.68B | $6.26B | $5.83B | $5.31B | $4.89B | $4.77B | $4.79B | $4.56B | $4.34B | $4.23B | |
| — | $2.69B | $2.67B | $2.72B | $2.56B | $2.45B | $2.3B | $2.06B | $1.99B | $1.91B | $1.78B | $1.67B | $1.74B | $1.72B | $1.67B | $1.56B | $1.65B | |
| — | $6.84B | $6.8B | $6.54B | $5.98B | $5.63B | $5.47B | $4.62B | $4.27B | $3.91B | $3.53B | $3.22B | $3.03B | $3.07B | $2.89B | $2.77B | $2.58B | |
| — | — | 71.84% | 70.62% | 70.03% | 69.63% | 70.38% | 69.18% | 68.18% | 67.19% | 66.55% | 65.92% | 63.53% | 64.12% | 63.41% | 63.95% | 60.97% | |
| — | $716M | $698M | $686M | $614M | $539M | $508M | $463M | $457M | $432M | $382M | $376M | $364M | $396M | $399M | $409M | $427M | |
| — | $2.39B | $2.38B | $2.32B | $2.15B | $2.01B | $2B | $1.73B | $1.64B | $1.48B | $1.33B | $1.36B | $1.53B | $1.64B | $1.61B | $1.47B | $1.45B | |
| — | $156M | $157M | $170M | $185M | $193M | $204M | $230M | $237M | $157M | $100M | $95M | $64M | $63M | $63M | $67M | $70M | |
| — | $487M | $487M | $497M | $491M | $465M | $448M | $441M | $412M | $308M | $242M | $240M | $199M | $204M | $209M | $200M | $205M | |
| — | — | $49M | $43M | $46M | $6M | $33M | $8M | $33M | $26M | $13M | $2M | $301M | $17M | $5M | $52M | — | |
| — | $230M | $222M | $225M | $239M | $221M | $224M | $231M | $223M | $206M | $175M | $166M | $124M | $117M | $113M | $31M | $36M | |
| — | $41M | $36M | $19M | $159M | -$40M | -$48M | -$17M | $57M | $83M | -$6M | $2M | -$81M | -$7M | $9M | $46M | -$48M | |
| — | $3.35B | $3.36B | $3.13B | $2.94B | $2.66B | $2.49B | $2B | $1.8B | $1.69B | $1.53B | $1.23B | $545M | $820M | $690M | $710M | $394M | |
| — | $673M | $687M | $637M | $596M | $545M | $454M | $360M | $301M | $266M | $663M | $409M | $206M | $233M | $187M | $274M | $146M | |
| — | $2.67B | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B | $1.64B | $1.5B | $1.43B | $864M | $821M | $339M | $583M | $504M | $436M | $245M | |
| — | — | 28.23% | 26.86% | 27.43% | 26.16% | 26.2% | 24.54% | 23.96% | 24.52% | 16.28% | 16.8% | 7.11% | 12.18% | 11.05% | 10.06% | 5.79% | |
| — | $0 | $0 | $10M | -$4M | -$3M | -$3M | -$2M | $0 | -$4M | -$2M | -$2M | $0 | $4M | -$1M | $0 | $3M | |
| — | $2.72B | $2.78B | $2.39B | $2.32B | $2.06B | $2B | $1.63B | $1.4B | $1.3B | $957M | $843M | $78M | $452M | $448M | $344M | $254M | |
| USD/shares | — | — | $6.03 | $5.47 | $5.08 | $4.51 | $4.29 | $3.44 | $3.14 | $2.96 | $1.76 | $1.66 | $0.68 | $1.16 | $1.01 | $0.87 | $0.49 |
| USD/shares | $6.85 – $7.00* | — | $6.02 | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 | $3.11 | $2.93 | $1.75 | $1.65 | $0.68 | $1.16 | $1.01 | $0.87 | $0.49 |
| shares | — | — | 443.44M | 454.2M | 461.17M | 468.89M | 474.35M | 475.5M | 478.13M | 483.06M | 489.92M | 495.72M | 499.71M | 501.06M | 500M | 500M | 500M |
| shares | — | — | 443.84M | 454.85M | 462.27M | 470.39M | 476.72M | 478.57M | 481.79M | 486.9M | 493.16M | 498.23M | 502.02M | 502.03M | 500.32M | 500M | 500M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2013–FY2025: $11.1B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.24×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.34×
P/E (TTM)
12.35×
Drug Manufacturers - Specialty & Generic median 20.32×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States Segment | $5,097,000,000 | $5,074,000,000 | $4,555,000,000 | $4,313,000,000 | $4,042,000,000 | $3,557,000,000 | $3,203,000,000 | $2,877,000,000 |
| International Segment | $4,254,000,000 | $4,102,000,000 | $3,911,000,000 | $3,681,000,000 | $3,652,000,000 | $3,035,000,000 | $2,972,000,000 | $2,890,000,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total Geographical Area | $9,351,000,000 | $9,176,000,000 | $8,466,000,000 | $7,994,000,000 | $7,694,000,000 | $6,592,000,000 | $6,175,000,000 | $5,767,000,000 |
| United States | $5,097,000,000 | $5,074,000,000 | $4,555,000,000 | $4,313,000,000 | $4,042,000,000 | $3,557,000,000 | $3,203,000,000 | $2,877,000,000 |
| Other Emerging Markets | $913,000,000 | $865,000,000 | $784,000,000 | $758,000,000 | $778,000,000 | $656,000,000 | $647,000,000 | $634,000,000 |
| Other Developed Markets | $641,000,000 | $564,000,000 | $512,000,000 | $468,000,000 | $467,000,000 | $388,000,000 | $370,000,000 | $361,000,000 |
| Brazil | $393,000,000 | $414,000,000 | $393,000,000 | $330,000,000 | $312,000,000 | $258,000,000 | $293,000,000 | $295,000,000 |
| Australia | $329,000,000 | $319,000,000 | $323,000,000 | $289,000,000 | $259,000,000 | $207,000,000 | $196,000,000 | $189,000,000 |
| United Kingdom | $325,000,000 | $314,000,000 | $277,000,000 | $235,000,000 | $234,000,000 | $178,000,000 | $198,000,000 | $181,000,000 |
| Canada | $290,000,000 | $277,000,000 | $255,000,000 | $238,000,000 | $232,000,000 | $210,000,000 | $206,000,000 | $203,000,000 |
| Germany | $236,000,000 | $225,000,000 | $202,000,000 | $176,000,000 | $183,000,000 | $159,000,000 | $153,000,000 | $147,000,000 |
| China | $227,000,000 | $270,000,000 | $320,000,000 | $382,000,000 | $357,000,000 | $266,000,000 | $200,000,000 | $211,000,000 |
| France | $165,000,000 | $156,000,000 | $142,000,000 | $126,000,000 | $132,000,000 | $118,000,000 | $117,000,000 | $130,000,000 |
| Mexico | $160,000,000 | $169,000,000 | $162,000,000 | $136,000,000 | $133,000,000 | $116,000,000 | $117,000,000 | $100,000,000 |
| Japan | $154,000,000 | $147,000,000 | $158,000,000 | $173,000,000 | $186,000,000 | $177,000,000 | $158,000,000 | $149,000,000 |
| Spain | $145,000,000 | $130,000,000 | $122,000,000 | $118,000,000 | $128,000,000 | $112,000,000 | $114,000,000 | $110,000,000 |
| Chile | $139,000,000 | $123,000,000 | $140,000,000 | $141,000,000 | $136,000,000 | $100,000,000 | $91,000,000 | $76,000,000 |
| Italy | $137,000,000 | $129,000,000 | $121,000,000 | $111,000,000 | $115,000,000 | $90,000,000 | $112,000,000 | $104,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total Products and Services | $9,351,000,000 | $9,176,000,000 | $8,466,000,000 | $7,994,000,000 | $7,694,000,000 | $6,592,000,000 | $6,175,000,000 | $5,767,000,000 |
| Companion Animal | $6,587,000,000 | $6,278,000,000 | $5,576,000,000 | $5,203,000,000 | $4,689,000,000 | $3,652,000,000 | $3,145,000,000 | $2,613,000,000 |
| Horses | $6,283,000,000 | $5,993,000,000 | $5,291,000,000 | $4,939,000,000 | $4,426,000,000 | $3,437,000,000 | $2,950,000,000 | $2,445,000,000 |
| Livestock | $2,764,000,000 | $2,898,000,000 | $2,890,000,000 | $2,791,000,000 | $3,005,000,000 | $2,940,000,000 | $3,030,000,000 | $3,154,000,000 |
| Parasiticides | $2,341,000,000 | $2,153,000,000 | $1,947,000,000 | $1,860,000,000 | $1,635,000,000 | $1,173,000,000 | $966,000,000 | $836,000,000 |
| Vaccines | $1,959,000,000 | $1,827,000,000 | $1,771,000,000 | $1,718,000,000 | $1,673,000,000 | $1,476,000,000 | $1,483,000,000 | $1,488,000,000 |
| Dermatology | $1,754,000,000 | $1,655,000,000 | $1,427,000,000 | $1,329,000,000 | $1,180,000,000 | $941,000,000 | $770,000,000 | $607,000,000 |
| Cattle | $1,492,000,000 | $1,531,000,000 | $1,503,000,000 | $1,440,000,000 | $1,557,000,000 | $1,558,000,000 | $1,654,000,000 | $1,754,000,000 |
| Anti Infective Products | $1,036,000,000 | $1,100,000,000 | $1,057,000,000 | $1,081,000,000 | $1,215,000,000 | $1,206,000,000 | $1,254,000,000 | $1,280,000,000 |
| Pain Sedation | $840,000,000 | $851,000,000 | $602,000,000 | $420,000,000 | — | — | — | — |
| Other Pharmaceuticals | $697,000,000 | $658,000,000 | $678,000,000 | $623,000,000 | $966,000,000 | $821,000,000 | $780,000,000 | $765,000,000 |
| Swine | $466,000,000 | $516,000,000 | $543,000,000 | $565,000,000 | $659,000,000 | $621,000,000 | $611,000,000 | $663,000,000 |
| Animal Health Diagnostics | $434,000,000 | $386,000,000 | $376,000,000 | $353,000,000 | $374,000,000 | $305,000,000 | $268,000,000 | $136,000,000 |
| Poultry | $432,000,000 | $527,000,000 | $524,000,000 | $476,000,000 | $507,000,000 | $537,000,000 | $559,000,000 | $522,000,000 |
| Dogs and Cats | $304,000,000 | $285,000,000 | $285,000,000 | $264,000,000 | $263,000,000 | $215,000,000 | $195,000,000 | $168,000,000 |
| Fish | $286,000,000 | $242,000,000 | $220,000,000 | $212,000,000 | $187,000,000 | $148,000,000 | $134,000,000 | $132,000,000 |
| Other Non-Pharmaceuticals | $263,000,000 | $253,000,000 | $254,000,000 | $250,000,000 | $231,000,000 | $210,000,000 | $184,000,000 | $170,000,000 |
| Contract Manufacturing and Human Health Diagnostics | $116,000,000 | $80,000,000 | $78,000,000 | $86,000,000 | $82,000,000 | $83,000,000 | $85,000,000 | $58,000,000 |
| Manufactured Product Other | $88,000,000 | $82,000,000 | $100,000,000 | $98,000,000 | $95,000,000 | $76,000,000 | $72,000,000 | $83,000,000 |
| Medicated Feed Additives | $27,000,000 | $293,000,000 | $354,000,000 | $360,000,000 | $420,000,000 | $460,000,000 | $470,000,000 | $485,000,000 |
Key facts
CIK
1555280
CUSIP
98978V103
13F (30d)
386 filings
382 filers
Visit website
Investor relations